How to strengthen New Zealand's proposed cannabis legalization and control bill

July 13, 2020

Two drug policy experts have identified gaps and challenges in New Zealand's proposal for legalizing recreational cannabis. In advance of a widely-watched national referendum vote to be held this September, Associate Professor Chris Wilkins and Dr. Marta Rychert of Massey University argue in the pages of Addiction that New Zealand's Cannabis Legislation and Control Bill (CLCB) needs to be strengthened in two critical areas:

Set a formal minimum price for cannabis: The legalization of cannabis in other jurisdictions has resulted in significant declines in the legal price of cannabis. Minimum unit pricing has been shown to be effective at reducing alcohol consumption levels and related harms. The CLCB includes a discretionary power to raise the excise tax for cannabis for a maximum of 12 months if the price of cannabis drops below the level consistent with purposes of the Act. This discretionary power lacks clear criteria for activation and thus falls short of a clear minimum price provision.

Lower the potency cap for cannabis products: High potency cannabis is associated with increasing first-time cannabis treatment admissions, transition to daily use, cannabis dependence and higher risk of psychosis and psychosis relapse. The CLCB's maximum potency levels for cannabis plant (15% THC) appears to be at the higher end of those currently found in the black market in New Zealand. Potency levels for edibles and extracts are expressed as milligrams "per unit" and "per package" without defining what constitutes a unit or package. (Edibles and concentrates will not initially be sold but they are included in the CLCB for future approval.)

Wilkins and Rychert also identify two public health objectives of the CLCB that will be difficult to achieve:

Difficulties reducing cannabis use over time via a commercial market: The CLCB largely proposes a commercial cannabis market with provisions for non-commercial and not-for-profit supply. The CLCB objective of lowering cannabis use over time appears at odds with the proposed commercial cannabis sector, which will focus on expanding sales. Non-commercial or not-for-profit operators can provide legal access to cannabis while avoiding profit driven commercial companies.

Difficulties taxing products by THC potency: The CLCB proposes a progressive product excise tax based on THC potency and weight. Considerable work will be required to implement a potency-based tax, including consistent sampling procedures, certified testing facilities, and effective auditing to prevent producers gaming the system. Also, the reliability and replicability of testing THC is problematic. A weight-based tax (similar to the taxation of tobacco) may be a more practical alternative for now.

Dr Wilkins says: "The New Zealand referendum vote will be the first time a country will have the opportunity to vote on a comprehensive regulatory framework to legalise cannabis rather than a general question asking whether cannabis should be legal or not. It's therefore important that New Zealand voters clearly understand the strengths and weaknesses of the proposed CLCB."

Wilkins and Rychert provided feedback on the first draft of the CLCB to the New Zealand Ministry of Justice Cannabis Referendum Team, along with a number of other anonymous experts and public commentators. The authors received no financial or non-financial remuneration for these comments.
For editors:

Peer reviewed: Yes
Type of study: Policy analysis
Subject of study: People
Funding: Government/research council

This paper is free to download for one month from the Wiley Online Library: or by contacting Jean O'Reilly, Editorial Manager, Addiction,

To speak with lead author Dr Chris Wilkins: contact him at Massey University (New Zealand) by email ( or telephone (+64 (09) 414 0800 ext. 41330).

Full citation for article: Wilkins C and Rychert M (2020) Assessing New Zealand's Cannabis Legalisation and Control Bill: Prospects and Challenges. Addiction 115: doi: 10.1111/add.15144.

Funding: The work in this paper was supported by external research funding from the New Zealand Royal Society Marsden Grant (MFP_MAU1813).

Addiction is a monthly international scientific journal publishing peer-reviewed research reports on alcohol, substances, tobacco, and gambling as well as editorials and other debate pieces. Owned by the Society for the Study of Addiction, it has been in continuous publication since 1884. Addiction is the number two journal in the 2019 ISI Journal Citation Reports ranking in the substance abuse category (science and social science editions).

Society for the Study of Addiction

Related Cannabis Articles from Brightsurf:

Cannabis to treat gynecological conditions
A significant number of women would consider using cannabis to treat gynecological conditions, primarily gynecological pain.

Cannabis data lacking, but machine learning could help
Everyone's heard of THC and CBD. But many other active compounds in cannabis interact to influence its effects.

Cannabis use for menopause symptom management
CLEVELAND, Ohio (September 28, 2020)--As legislation relaxes regarding cannabis, it is being used to manage numerous chronic health conditions and mood symptoms.

Prescribed CBD could help people quit cannabis
A benchmark clinical trial published today shows that cannabidiol (CBD) could be a safe and effective treatment for problematic cannabis use.

Pregnant women with depression are more than 3 times more likely to use cannabis
Cannabis use is much more common among pregnant women with depression and pregnant women with depression are more than 3 times more likely to use cannabis than those without depression.

Cannabis compound acts as an antibiotic 
Public health agencies worldwide have identified antibiotic resistance of disease-causing bacteria as one of humanity's most critical challenges.

Cannabis use during pregnancy
The large health care system Kaiser Permanente Northern California provides universal screening for prenatal cannabis use in women during pregnancy by self-report and urine toxicology testing.

Questions and answers about cannabis use during pregnancy
A new study shows that women have many medical questions about the use of cannabis both before and during pregnancy, and during the postpartum period while breastfeeding.

Managing cannabis use in breastfeeding women
As more states legalize medicinal and recreational cannabis use and increasingly decriminalize cannabis, the risk to the growth and development of breastfeeding infants whose mothers use cannabis becomes a growing public health concern.

Cannabis edibles present novel health risks
With the recent legalization of cannabis edibles in Canada, physicians and the public must be aware of the novel risks of cannabis edibles, argue authors in a commentary in CMAJ (Canadian Medical Association Journal).

Read More: Cannabis News and Cannabis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to